Figure 4 | Scientific Reports

Figure 4

From: Gene therapy of prostate cancer using liposomes containing perforin expression vector driven by the promoter of prostate-specific antigen gene

Figure 4

Anti-tumor effect of liposomes encapsulating PSA promoter-driven perforin expression vector in vitro. 22Rv1DR and PC-3 cells (1.0 × 103) cells were seeded on 96-well plates. (A) and (B) Twenty-four h later, empty Lipo (1.89 μg of lipid/well), human PBMCs (2.0 × 104) or both were added. (C) and (D) Twenty-four h later, pLipo at a low concentration (5.0 ng of perforin expression vector/well), human PBMCs (2.0 × 104) or both were added. (E) and (F) Twenty-four h later, pLipo at a high concentration (169.0 ng of perforin expression vector/well), human PBMCs (2.0 × 104) or both were added. Cell viability was determined by WST-1 assay 3 to 7 days after treatment. Data shown are mean with SD (n = 5 in each group). Statistical significance was calculated using one-way ANOVA with Turkey’s multiple comparison test. (G) White light microscopic Image of cells treated with pLipo at a high concentration with or without PBMCs were taken 7 days after treatment.

Back to article page